Transcription factor AP-2α regulates acute myeloid leukemia cell proliferation by influencing Hoxa gene expression

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 8, 2013, Pages 1647-1656

  Ding, Xiaofeng ^a   Yang, Zijian ^a   Zhou, Fangliang ^a   Wang, Fangmei ^a   Li, Xinxin ^a   Chen, Cheng ^a   Li, Xiaofeng ^a   Hu, Xiang ^a   Xiang, Shuanglin ^a   Zhang, Jian ^a  

^a HUNAN NORMAL UNIVERSITY   (China)

Author keywords

AML; AP 2 ; Hoxa7; Hoxa9; Meis1

Indexed keywords

LUCIFERASE; MEIS1 PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2ALPHA PROTEIN; TRANSCRIPTION FACTOR HOXA7 PROTEIN; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER INHIBITION; CARCINOGENICITY; CELL GROWTH; CELL LEVEL; CELL PROLIFERATION; CHROMATIN; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LEUKEMIA CELL; LEUKEMOGENESIS; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

MAMMALIA;

EID: 84884836080     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.04.024     Document Type: Article

References (57)

1. Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjanen K, et al. Expression of transcription factor AP-2alpha predicts survival in epithelial ovar-ian cancer. British Journal of Cancer 2000;82:1974-83.. (Pubitemid 30326459)
2. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and theAP-2gamma transcription factor. Cancer Research 2004;64:8256-61.. (Pubitemid 39491763)
3. Auman HJ, Nottoli T, Lakiza O, Winger Q, Donaldson S, Williams T. Transcrip-tion factor AP-2gamma is essential in the extra-embryonic lineages for earlypostimplantation development. Development 2002;129:2733-47.. (Pubitemid 34874256)
4. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcriptionfactor. Pigment Cell Research 2001;14:78-85.. (Pubitemid 32258344)
5. Cairns BR, Henry NL, Kornberg RD. TFG/TAF30/ANC1, a component of the yeastSWI/SNF complex that is similar to the leukemogenic proteins ENL and AF-9. Molecular and Cellular Biology 1996;16:3308-16.. (Pubitemid 26199850)
6. Campillos M, Garcia MA, Valdivieso F, Vazquez J. Transcriptional activationby AP-2alpha is modulated by the oncogene DEK. Nucleic Acids Research 2003;31:1571-5.. (Pubitemid 36304919)
7. Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A, et al. The tumor suppressormenin regulates hematopoiesis and myeloid transformation by influencing Hoxgene expression. Proceedings of the National Academy of Sciences of the United States of America 2006;103:1018-23.. (Pubitemid 43212214)
8. Debernardi S, Bassini A, Jones LK, Chaplin T, Linder B, de Bruijn DR, et al. The MLL fusion partner AF10 binds GAS41, a protein that interacts with the humanSWI/SNF complex. Blood 2002;99:275-81..
9. Ding X, Fan C, Zhou J, Zhong Y, Liu R, Ren K, et al. GAS41 interacts with transcrip-tion factor AP-2beta and stimulates AP-2beta-mediated transactivation. Nucleic Acids Research 2006;34:2570-8.. (Pubitemid 43985621)
10. Ding X, Luo C, Zhou J, Zhong Y, Hu X, Zhou F, et al. The interaction of KCTD1 withtranscription factor AP-2alpha inhibits its transactivation. Journal of Cellular Biochemistry 2009;106:285-95..
11. Doerksen LF, Bhattacharya A, Kannan P, Pratt D, Tainsky MA. Functional interactionbetween a RARE and an AP-2 binding site in the regulation of the human HOXA4 gene promoter. Nucleic Acids Research 1996;24:2849-56.. (Pubitemid 26239759)
12. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diag-nosis and management of acute myeloid leukemia in adults: recommendationsfrom an international expert panel, on behalf of the European Leukemia Net. Blood 2010;115:453-74..
13. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, et al. Hypermethylation of a small CpGuanine-rich region correlates with loss of acti-vator protein-2alpha expression during progression of breast cancer. Cancer Research 2004;64:1611-20.. (Pubitemid 38428681)
14. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-907.. (Pubitemid 44794525)
15. Favier B, Dolle P. Developmental functions of mammalian Hox genes. Molecular Human Reproduction 1997;3:115-31.. (Pubitemid 127509441)
16. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecularclassification of cancer: class discovery and class prediction by gene expressionmonitoring. Science 1999;286:531-7..
17. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, et al. Loss of theAP-2alpha transcription factor is associated with the grade of human gliomas. Clinical Cancer Research 2005;11:267-72.. (Pubitemid 40075804)
18. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis byoverlap extension using the polymerase chain reaction. Gene 1989;77:51-9.. (Pubitemid 19125653)
19. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M. Loss of AP-2 results in downregu-lation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO Journal 1998;17:4358-69.. (Pubitemid 28362626)
20. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction bytwo different signal-transduction pathways: protein kinase C and cAMP. Cell 1987;51:251-60..
21. Kannan P, Buettner R, Chiao PJ, Yim SO, Sarkiss M, Tainsky MA. N-ras oncogenecauses AP-2 transcriptional self-interference, which leads to transformation. Genes and Development 1994;8:1258-69.. (Pubitemid 24181318)
22. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Downregulationof transcription factor AP-2 predicts poor survival in stage I cutaneous malignantmelanoma. Journal of Clinical Oncology 1998;16:3584-91.. (Pubitemid 28506772)
23. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9transforms primary bone marrow cells through specific collaboration withMeis1a but not Pbx1b. EMBO Journal 1998;17:3714-25.. (Pubitemid 28327389)
24. Lipponen P, Aaltomaa S, Kellokoski J, Ala-Opas M, Kosma V. Expression of acti-vator protein 2 in prostate cancer is related to tumor differentiation and cellproliferation. European Urology 2000;37:573-8.. (Pubitemid 30189826)
25. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002;295:868-72.. (Pubitemid 34118370)
26. Maa MC, Hsieh CY, Leu TH. Overexpression of p97Eps8 leads to cellular transfor-mation: implication of pleckstrin homology domain in p97Eps8-mediated ERKactivation. Oncogene 2001;20:106-12..
27. Maconochie M, Krishnamurthy R, Nonchev S, Meier P, Manzanares M, Mitchell PJ, et al. Regulation of Hoxa2 in cranial neural crest cells involves members of theAP-2 family. Development 1999;126:1483-94.. (Pubitemid 29195237)
28. McPherson LA, Weigel RJ. AP2alpha and AP2gamma: a comparison of bind-ing site specificity and trans-activation of the estrogen receptor promoterand single site promoter constructs. Nucleic Acids Research 1999;27:4040-9.. (Pubitemid 29479031)
29. Mitchell PJ, Wang C, Tjian R. Positive and negative regulation of transcriptionin vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell 1987;50:847-61..
30. Moser M, Pscherer A, Roth C, Becker J, Mucher G, Zerres K, et al. Enhanced apoptoticcell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes and Development 1997;11:1938-48.. (Pubitemid 27332981)
31. Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM. Meis1, a PBX1-relatedhomeobox gene involved in myeloid leukemia in BXH-2 mice. Molecular andCellular Biology 1995;15:5434-43..
32. Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosometranslocation t(7;11)(p15;p15) in human myeloid leukaemia. Nature Genetics 1996a;12:154-8.. (Pubitemid 26051295)
33. Nakamura T, Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Cooper-ative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nature Genetics 1996b;12:149-53.. (Pubitemid 26051294)
34. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L links histonemethylation to leukemogenesis. Cell 2005;121:167-78..
35. Orlovsky K, Kalinkovich A, Rozovskaia T, Shezen E, Itkin T, Alder H, et al. Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearrangedacute leukemia impairs engraftment and reduces proliferation. Proceedingsof the National Academy of Sciences of the United States of America 2011;108:7956-61..
36. Pellikainen J, Kataja V, Ropponen K, Kellokoski J, Pietilainen T, Bohm J, et al. Reducednuclear expression of transcription factor AP-2 associates with aggressive breastcancer. Clinical Cancer Research 2002;8:3487-95.. (Pubitemid 35340726)
37. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, et al. Expression of HER2 and its association with AP-2 in breast cancer. European Journal of Cancer 2004;40:1485-95.. (Pubitemid 38757735)
38. Pellikainen JM, Kosma VM. Activator protein-2 in carcinogenesis with a specialreference to breast cancer - a mini review. International Journal of Cancer 2007;120:2061-7.. (Pubitemid 46555842)
39. Prasad R, Yano T, Sorio C, Nakamura T, Rallapalli R, Gu Y, et al. Domains with trans-criptional regulatory activity within the ALL1 and AF4 proteins involved in acuteleukemia. Proceedings of the National Academy of Sciences of the United Statesof America 1995;92:12160-4.. (Pubitemid 26014030)
40. Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatment of acutemyeloid leukemia. Cancer 2007;110:1900-10..
41. Rawat VP, Thoene S, Naidu VM, Arseni N, Heilmeier B, Metzeler K, et al. Over-expression of CDX2 perturbs HOX gene expression in murine progenitorsdepending on its N-terminal domain and is closely correlated with deregu-lated HOX gene expression in human acute myeloid leukemia. Blood 2008;111:309-19..
42. Ropponen KM, Kellokoski JK, Lipponen PK, Pietilainen T, Eskelinen MJ, Alhava EM, et al. p22/WAF1 expression in human colorectal carcinoma: associationwith p53, transcription factor AP-2 and prognosis. British Journal of Cancer 1999;81:133-40.. (Pubitemid 29415503)
43. Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM, et al. Expression of transcription factor AP-2 in colorectal adenomas and adenocarci-nomas; comparison of immunohistochemistry and in situ hybridisation. Journalof Clinical Pathology 2001;54:533-8.. (Pubitemid 32642942)
44. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2alphainhibits tumorigenicity and represses vascular endothelial growth factor tran-scription in prostate cancer cells. Cancer Research 2004;64:631-8.. (Pubitemid 38120903)
45. Samuel S, Naora H. Homeobox gene expression in cancer: insights fromdevelopmental regulation and deregulation. European Journal of Cancer 2005;41:2428-37.. (Pubitemid 41540620)
46. Schnabel CA, Jacobs Y, Cleary ML. HoxA9-mediated immortalization of myeloidprogenitors requires functional interactions with TALE cofactors Pbx and Meis. Oncogene 2000;19:608-16.. (Pubitemid 30102911)
47. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ, et al. Lossof AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increasein tumorigenicity of colon cancer cells in vivo. Oncogene 2007;26:4049-58.. (Pubitemid 46920174)
48. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires thetranscriptional transactivation activity of ENL and the DNA binding motifs ofHRX. Molecular and Cellular Biology 1998;18:122-9.. (Pubitemid 28021024)
49. So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. Leukemic transformationof hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 2004;103:3192-9.. (Pubitemid 38451698)
50. Tan CC, Sindhu KV, Li S, Nishio H, Stoller JZ, Oishi K, et al. Transcription factorAp2delta associates with Ash2l and ALR, a trithorax family histone methyltrans-ferase, to activate Hoxc8 transcription. Proceedings of the National Academy ofSciences of the United States of America 2008;105:7472-7.. (Pubitemid 351830042)
51. Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2alpha resultsin overexpression of protease-activated receptor-1 and correlates with themalignant phenotype of human melanoma. Journal of Biological Chemistry 2003;278:46632-42.. (Pubitemid 37452239)
52. Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, et al. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation ofmultiple growth factor signalling pathways. Cancer Research 1998;58:5466-72.. (Pubitemid 28551131)
53. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U, et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortaliza-tion. Molecular and Cellular Biology 2004;24:617-28.. (Pubitemid 38057914)
54. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and acti-vates p21WAF1/CIP1 expression. Nature Genetics 1997;15:78-82.. (Pubitemid 27014954)
55. Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMa-hon AP, et al. Neural tube, skeletal and body wall defects in mice lackingtranscription factor AP-2. Nature 1996;381:238-41.. (Pubitemid 26148033)
56. Zhou J, Fan C, Zhong Y, Liu Y, Liu M, Zhou A, et al. Genomic organization, promotercharacterization and roles of Sp1 and AP-2 in the basal transcription of mousePDIP1 gene. FEBS Letters 2005;579:1715-22.. (Pubitemid 40341548)
57. Zimmermann K, Ahrens K, Matthes S, Buerstedde JM, Stratling WH, Phi-van L. Tar-geted disruption of the GAS41 gene encoding a putative transcription factorindicates that GAS41 is essential for cell viability. Journal of Biological Chemistry 2002;277:18626-31.. (Pubitemid 34952417)